Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure
- 5 November 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 106 (19) , 2454-2458
Abstract
Background— Brain natriuretic peptide (BNP) and norepinephrine (NE) are strongly related to severity of and are independent predictors of outcome in heart failure. The long-term effects of angiotensin receptor blockers on BNP and NE in heart failure patients are not known. Methods and Results— Both BNP and NE were measured in 4284 patients randomized to valsartan or placebo in the Valsartan Heart Failure Trial (Val-HeFT) at baseline and 4, 12, and 24 months after randomization. The effects of valsartan were tested by ANCOVA, controlling for baseline values and concomitant ACE inhibitors and/or β-blockers. BNP and NE concentrations were similar at baseline in the 2 groups and were decreased by valsartan starting at 4 months and up to 24 months. BNP increased over time in the placebo group. At the end point, least-squares mean (±SEM) BNP increased from baseline by 23±5 pg/mL in the placebo group (n=1979) but decreased by 21±5 pg/mL (n=1940) in the valsartan group ( P P =0.0003). Concomitant therapy with both ACE inhibitors and β-blockers significantly reduced the effect of valsartan on BNP but not on NE ( P for interaction=0.0223 and 0.2289, respectively). Conclusions— In Val-HeFT, the largest neurohormone study in patients with symptomatic chronic heart failure, BNP and NE rose over time in the placebo group. Valsartan caused sustained reduction in BNP and attenuated the increase in NE over the course of the study. These neurohormone effects of valsartan are consistent with the clinical benefits reported in Val-HeFT.Keywords
This publication has 12 references indexed in Scilit:
- Neurohormonal blockade in chronic heart failureJACC, 2001
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Role of brain natriuretic peptide in risk stratification of patients with congestive heart failureJACC, 2001
- A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart FailureNew England Journal of Medicine, 2001
- Effects of ??-Blockers on Neurohormonal Activation in Patients with Congestive Heart FailureDrugs, 2000
- Natriuretic PeptidesNew England Journal of Medicine, 1998
- Potentiation of Natriuretic Peptide Action by the β -Adrenergic Blocker Carvedilol in Hypertensive Rats: A New Antihypertensive Mechanism1Endocrinology, 1998
- Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunctionThe American Journal of Cardiology, 1995
- Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the registry of studies of left ventricular dysfunctionJACC, 1994
- II. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in manLife Sciences, 1981